Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galmed Pharmaceuticals Ltd. (GLMD : NSDQ)

• Company Description    Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $1.21 Daily Weekly Monthly 20 Day Moving Average: 69,759 shares Shares Outstanding: 1.65 (millions) Market Capitalization: $1.99 (millions) Beta: 0.49 52 Week High: $3.61 52 Week Low: $1.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.14% -17.36% 12 Week -16.32% -19.79% Year To Date -62.23% -66.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 16 ABBA HILLEL ROAD - RAMAT GAN,L3 5250608 ISR ph: 972-3693-8448 fax: 972-3693-8447 investor.relations@galmedpharma.com http://www.galmedpharma.com

• General Corporate Information    Officers Allen Baharaff - Chief Executive Officer and President Amir Poshinski - Chairman Guy Nehemya - Chief Operating Officer Doron Cohen - Chief Financial Officer Yohai Stenzler - Chief Accounting Officer Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: M47238148 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 1.65 Most Recent Split Date: 8.00 (0.08:1) Beta: 0.49 Market Capitalization: $1.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.10 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 250.00% vs. Previous Quarter: 201.61% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -20.69 03/31/25 - -32.21 ROA 09/30/25 - - 06/30/25 - -18.41 03/31/25 - -28.59 Current Ratio 09/30/25 - - 06/30/25 - 8.71 03/31/25 - 9.02 Quick Ratio 09/30/25 - - 06/30/25 - 8.71 03/31/25 - 9.02 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 12.40 03/31/25 - 10.20 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©